ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,219Medicare Part D Prescriptions Filled, Including Refills

Rank: 536 out of 1499

$679K Total Retail Price of All Prescriptions

Rank: 182 out of 1499

158 Patients Receiving at Least One Drug in Part D
57%Patients 65 Years and Older
84% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Missouri
Lower avg

Schedule Two
Controlled Substances

25% of this provider’s 158 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

23% of this provider’s 158 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

3% of this provider’s 3,054 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

42% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$94 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

46 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Missouri
ALLOPURINOL 258 136 1 36
LOSARTAN POTASSIUM 210 120 2 26
CRESTOR 193 58 3 34
HYDROCODONE-ACETAMINOPHEN 167 73 S3 4 4
PRAVASTATIN SODIUM 140 97 5 18
LISINOPRIL 135 93 6 1
LYRICA 132 26 7 90
HYDROXYCHLOROQUINE SULFATE 124 48 8 365
AMLODIPINE BESYLATE 119 72 9 6
CARVEDILOL 119 78 9 22
METFORMIN HCL ER 113 66 11 53
DIOVAN 111 31 12 58
LEVOTHYROXINE SODIUM 108 60 13 2
NEXIUM 101 44 14 28
SPIRONOLACTONE 97 28 15 61
DALIRESP 95 0 16 255
FENOFIBRATE 94 50 17 66
SPIRIVA 94 0 17 44
OMEPRAZOLE 88 30 19 5
NAMENDA 87 36 20 47
MELOXICAM 79 36 21 27
ADVAIR DISKUS 79 15 21 37
ENABLEX 78 24 23 220
ALENDRONATE SODIUM 77 54 24 33
RANITIDINE HCL 77 0 24 15
ZETIA 76 36 26 91
CHLORTHALIDONE 74 29 27 168
OLANZAPINE 71 39 28 140
OXYCONTIN 71 28 S2 28 99
BUTRANS 69 0 S3 30 421
CYMBALTA 69 32 30 40
BYSTOLIC 66 13 32 108
EXELON 65 38 33 166
RIVASTIGMINE 63 41 34 434
METHOTREXATE 62 28 35 236
HYDRALAZINE HCL 62 39 35 118
GABAPENTIN 59 17 37 13
ROPINIROLE HCL 57 35 38 55
PRENATAL PLUS 57 12 38 157
SINGULAIR 55 12 40 67
JANUVIA 55 0 40 84
PEN NEEDLE 55 12 40 120
TAMSULOSIN HCL 54 24 43 29
JANUMET 53 31 44 226
CYCLOBENZAPRINE HCL 52 13 R 45 41
TEKTURNA 51 17 46 269
LEVEMIR FLEXPEN 51 11 46 235
ATORVASTATIN CALCIUM 51 22 46 17
TRADJENTA 50 21 49 475
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 28, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.